3164 — GenMont Biotech Income Statement
0.000.00%
Last trade - 00:00
- TWD2.00bn
- TWD1.87bn
- TWD318.02m
- 36
- 23
- 32
- 16
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 346 | 325 | 428 | 369 | 318 |
Cost of Revenue | |||||
Gross Profit | 230 | 215 | 299 | 257 | 211 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 278 | 247 | 303 | 307 | 311 |
Operating Profit | 68.7 | 78.5 | 125 | 62 | 6.99 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 75.5 | 76.8 | 139 | 66.3 | 28.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | 57.2 | 60.2 | 110 | 47.5 | 22.4 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 57.5 | 60.9 | 113 | 57 | 33 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 57.5 | 60.9 | 113 | 57 | 33 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.72 | 0.623 | 1.27 | 0.658 | 0.378 |
Dividends per Share |